ROIV Stock Overview
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Roivant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.16 |
| 52 Week High | US$13.06 |
| 52 Week Low | US$8.56 |
| Beta | 1.24 |
| 11 Month Change | -6.38% |
| 3 Month Change | -2.79% |
| 1 Year Change | 26.82% |
| 33 Year Change | 41.80% |
| 5 Year Change | n/a |
| Change since IPO | 7.31% |
Recent News & Updates
Recent updates
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Oct 22Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position
Aug 22
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts
Nov 15Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?
Apr 26Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher
Nov 22Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts
Sep 29Shareholder Returns
| ROIV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.5% | -10.5% | -2.1% |
| 1Y | 26.8% | 12.7% | 29.7% |
Return vs Industry: ROIV exceeded the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: ROIV underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ROIV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ROIV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 908 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
Roivant Sciences Ltd. Fundamentals Summary
| ROIV fundamental statistics | |
|---|---|
| Market cap | US$8.15b |
| Earnings (TTM) | US$4.60b |
| Revenue (TTM) | US$129.13m |
1.8x
P/E Ratio62.9x
P/S RatioIs ROIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROIV income statement (TTM) | |
|---|---|
| Revenue | US$129.13m |
| Cost of Revenue | US$552.21m |
| Gross Profit | -US$423.08m |
| Other Expenses | -US$5.02b |
| Earnings | US$4.60b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.31 |
| Gross Margin | -327.64% |
| Net Profit Margin | 3,558.52% |
| Debt/Equity Ratio | 0% |
How did ROIV perform over the long term?
See historical performance and comparison